EFG Asset Management Americas Corp. acquired a new stake in shares of Iqvia Holdings Inc (NYSE:IQV) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,053 shares of the medical research company’s stock, valued at approximately $291,000.
Other institutional investors have also bought and sold shares of the company. Advisors Asset Management Inc. lifted its stake in shares of Iqvia by 96.7% in the 4th quarter. Advisors Asset Management Inc. now owns 720 shares of the medical research company’s stock valued at $111,000 after purchasing an additional 354 shares during the last quarter. Sunbelt Securities Inc. acquired a new position in Iqvia in the fourth quarter valued at about $5,408,000. Foundations Investment Advisors LLC boosted its position in Iqvia by 12.7% in the first quarter. Foundations Investment Advisors LLC now owns 8,674 shares of the medical research company’s stock valued at $868,000 after buying an additional 975 shares in the last quarter. State of Alaska Department of Revenue boosted its position in Iqvia by 7.6% in the first quarter. State of Alaska Department of Revenue now owns 78,186 shares of the medical research company’s stock valued at $8,432,000 after buying an additional 5,543 shares in the last quarter. Finally, Gradient Investments LLC acquired a new position in Iqvia in the first quarter valued at about $3,335,000. Hedge funds and other institutional investors own 88.49% of the company’s stock.
In other Iqvia news, insider Ari Bousbib sold 19,443 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $150.00, for a total transaction of $2,916,450.00. Following the completion of the sale, the insider now directly owns 671,478 shares in the company, valued at approximately $100,721,700. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Group Holdings (Sbs) Advis Tpg sold 2,919,051 shares of the business’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $159.12, for a total value of $464,479,395.12. The disclosure for this sale can be found here. Insiders have sold 2,984,574 shares of company stock valued at $474,768,645 in the last three months. Insiders own 6.00% of the company’s stock.
Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, July 22nd. The medical research company reported $1.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.12. Iqvia had a net margin of 1.21% and a return on equity of 17.90%. The company had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the prior year, the business earned $1.53 earnings per share. On average, equities analysts anticipate that Iqvia Holdings Inc will post 5.72 EPS for the current fiscal year.
IQV has been the topic of several analyst reports. Stifel Nicolaus increased their price objective on shares of Iqvia from $159.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Wells Fargo & Co upped their target price on shares of Iqvia from $155.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Deutsche Bank increased their price objective on shares of Iqvia from $145.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, July 23rd. Piper Sandler increased their price objective on shares of Iqvia from $115.00 to $138.00 in a research report on Wednesday, April 29th. Finally, Bank of America increased their target price on shares of Iqvia from $145.00 to $156.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $165.11.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.